Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/81969
| Title: | Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure : virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates | Authors: | Chen, YW Yiu, CPB Wong, KY |
Issue Date: | 2020 | Source: | F1000Research, 2020, v. 9, 129, p. 1-16 | Abstract: | We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CL pro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 3C-like cleavage sites on the coronaviral polyproteins are highly conserved. Based on the near-identical substrate specificities and high sequence identities, we are of the opinion that some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart. With the 3CL pro molecular model, we performed virtual screening for purchasable drugs and proposed 16 candidates for consideration. Among these, the antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache. The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes. | Keywords: | 2019-nCoV 3C-like protease Antiviral Coronavirus COVID-19 Drug repurpose HCV Hepatitis C virus Ledipasvir Molecular modelling SARS Velpatasvir Virtual screening |
Publisher: | F1000 Research | Journal: | F1000Research | EISSN: | 2046-1402 | DOI: | 10.12688/f1000research.22457.1 | Rights: | © 2020 Chen YW et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The following publication Chen YW, Yiu CPB and Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 1; peer review: 3 approved]. F1000Research 2020, 9:129 is available at https://dx.doi.org/10.12688/f1000research.22457.1 |
| Appears in Collections: | Journal/Magazine Article |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Chen_2019-nCoV_3C-like_3CL.pdf | 761.89 kB | Adobe PDF | View/Open |
Access
View full-text via PolyU eLinks 
Page views
196
Last Week
3
3
Last month
Citations as of Jun 4, 2023
Downloads
75
Citations as of Jun 4, 2023
SCOPUSTM
Citations
321
Citations as of Jun 1, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.